XERS
Xeris Pharmaceuticals Inc
8.70$
-0.8%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -8.1% | -8.5% | +18.3% | +12.9% | +10.7% | +0.0% | +19.0% | +4.0% | +15.4% | -3.1% | +10.8% | – | |
| – | +25.4% | -41.9% | +75.8% | +29.5% | -30.3% | -7.9% | +67.4% | -24.7% | +73.5% | -30.4% | -5.8% | – | |
| – | -15.0% | +1.6% | +8.4% | +8.3% | +24.5% | +1.5% | +10.8% | +11.3% | +5.3% | +4.7% | +14.0% | – | |
| – | +26.8% | +22.5% | -26.4% | +2.2% | +3.5% | +27.3% | +3.9% | -7.1% | +5.2% | +11.5% | +21.5% | – | |
| – | +0.8% | +2.2% | +4.2% | +12.4% | -10.7% | +9.7% | +0.9% | +4.7% | +2.2% | +11.9% | +14.8% | – | |
| – | -2.4% | +11.3% | -6.5% | +17.1% | -8.6% | +11.3% | -3.7% | +8.0% | -11.8% | +24.0% | +20.2% | – | |
| – | – | – | – | – | – | -284.0% | – | +50.2% | +149.2% | -52.8% | -34.7% | – | |
| – | +2.5% | +0.2% | +13.3% | -2.2% | -1.1% | -5.2% | +0.7% | -1.2% | -1.6% | -3.8% | +0.9% | – | |
| – | – | – | – | – | – | – | – | – | +1,684.4% | -79.8% | -1,492.2% | – | |
| – | – | – | +144.0% | -543.8% | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | +1,684.4% | -79.8% | -1,492.2% | – | |
| – | – | – | – | – | – | -78.5% | +599.8% | +28.9% | +27.5% | -12.7% | -271.3% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.